BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 19744744)

  • 21. Novel immunocytokine IL12-SS1 (Fv) inhibits mesothelioma tumor growth in nude mice.
    Kim H; Gao W; Ho M
    PLoS One; 2013; 8(11):e81919. PubMed ID: 24260587
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Establishment of novel mAb to human ERC/mesothelin useful for study and diagnosis of ERC/mesothelin-expressing cancers.
    Ishikawa K; Segawa T; Hagiwara Y; Maeda M; Abe M; Hino O
    Pathol Int; 2009 Mar; 59(3):161-6. PubMed ID: 19261093
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Mesothelin in ovarian cancer].
    Fraszczak K; Barczyński B; Polak G; Kułak K; Kotarski J
    Pol Merkur Lekarski; 2013 Sep; 35(207):166-70. PubMed ID: 24224456
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of anti-C-ERC/mesothelin monoclonal antibody in vivo.
    Inami K; Abe M; Takeda K; Hagiwara Y; Maeda M; Segawa T; Suyama M; Watanabe S; Hino O
    Cancer Sci; 2010 Apr; 101(4):969-74. PubMed ID: 20100205
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Does CA125 binding to mesothelin impact the detection of malignant mesothelioma?
    Creaney J; Dick IM; Dare H; Demelker Y; Nowak AK; Musk AW; Robinson BW
    Lung Cancer; 2013 Apr; 80(1):39-44. PubMed ID: 23357461
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Value of mesothelin immunostaining in the diagnosis of mesothelioma.
    Ordóñez NG
    Mod Pathol; 2003 Mar; 16(3):192-7. PubMed ID: 12640097
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characterization of crystals of an antibody-recognition fragment of the cancer differentiation antigen mesothelin in complex with the therapeutic antibody MORAb-009.
    Ma J; Tang WK; Esser L; Pastan I; Xia D
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2012 Aug; 68(Pt 8):950-3. PubMed ID: 22869130
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies.
    Beatty GL; Haas AR; Maus MV; Torigian DA; Soulen MC; Plesa G; Chew A; Zhao Y; Levine BL; Albelda SM; Kalos M; June CH
    Cancer Immunol Res; 2014 Feb; 2(2):112-20. PubMed ID: 24579088
    [TBL] [Abstract][Full Text] [Related]  

  • 29. CA125 suppresses amatuximab immune-effector function and elevated serum levels are associated with reduced clinical response in first line mesothelioma patients.
    Nicolaides NC; Schweizer C; Somers EB; Wang W; Fernando S; Ross EN; Grasso L; Hassan R; Kline JB
    Cancer Biol Ther; 2018 Jul; 19(7):622-630. PubMed ID: 29652548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of a CA125-mesothelin cell adhesion assay as a screening tool for biologics discovery.
    Scholler N; Garvik B; Hayden-Ledbetter M; Kline T; Urban N
    Cancer Lett; 2007 Mar; 247(1):130-6. PubMed ID: 16677756
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sensitive and specific new enzyme-linked immunosorbent assay for N-ERC/mesothelin increases its potential as a useful serum tumor marker for mesothelioma.
    Shiomi K; Hagiwara Y; Sonoue K; Segawa T; Miyashita K; Maeda M; Izumi H; Masuda K; Hirabayashi M; Moroboshi T; Yoshiyama T; Ishida A; Natori Y; Inoue A; Kobayashi M; Sakao Y; Miyamoto H; Takahashi K; Hino O
    Clin Cancer Res; 2008 Mar; 14(5):1431-7. PubMed ID: 18316566
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of mesothelin and exploiting it as a target for immunotherapy.
    Pastan I; Hassan R
    Cancer Res; 2014 Jun; 74(11):2907-12. PubMed ID: 24824231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
    Creaney J; van Bruggen I; Hof M; Segal A; Musk AW; de Klerk N; Horick N; Skates SJ; Robinson BW
    Chest; 2007 Oct; 132(4):1239-46. PubMed ID: 17646232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
    Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
    Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of mesothelin expression by mesothelioma cells grown in vitro determines sensitivity to anti-mesothelin immunotoxin SS1P.
    Zhang J; Qiu S; Zhang Y; Merino M; Fetsch P; Avital I; Filie A; Pastan I; Hassan R
    Anticancer Res; 2012 Dec; 32(12):5151-8. PubMed ID: 23225411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A novel high-affinity human monoclonal antibody to mesothelin.
    Ho M; Feng M; Fisher RJ; Rader C; Pastan I
    Int J Cancer; 2011 May; 128(9):2020-30. PubMed ID: 20635390
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Assessment of the clinicopathological relevance of mesothelin level in plasma, peritoneal fluid, and tumor tissue of epithelial ovarian cancer patients.
    Okła K; Surówka J; Frąszczak K; Czerwonka A; Kaławaj K; Wawruszak A; Kotarski J; Wertel I
    Tumour Biol; 2018 Oct; 40(10):1010428318804937. PubMed ID: 30319054
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients.
    Shiomi K; Miyamoto H; Segawa T; Hagiwara Y; Ota A; Maeda M; Takahashi K; Masuda K; Sakao Y; Hino O
    Cancer Sci; 2006 Sep; 97(9):928-32. PubMed ID: 16776777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comprehensive immunohistochemical study of mesothelin (MSLN) using different monoclonal antibodies 5B2 and MN-1 in 1562 tumors with evaluation of its prognostic value in malignant pleural mesothelioma.
    Inaguma S; Wang Z; Lasota J; Onda M; Czapiewski P; Langfort R; Rys J; Szpor J; Waloszczyk P; Okoń K; Biernat W; Ikeda H; Schrump DS; Hassan R; Pastan I; Miettinen M
    Oncotarget; 2017 Apr; 8(16):26744-26754. PubMed ID: 28460459
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A novel mycobacterial Hsp70-containing fusion protein targeting mesothelin augments antitumor immunity and prolongs survival in murine models of ovarian cancer and mesothelioma.
    Yuan J; Kashiwagi S; Reeves P; Nezivar J; Yang Y; Arrifin NH; Nguyen M; Jean-Mary G; Tong X; Uppal P; Korochkina S; Forbes B; Chen T; Righi E; Bronson R; Chen H; Orsulic S; Brauns T; Leblanc P; Scholler N; Dranoff G; Gelfand J; Poznansky MC
    J Hematol Oncol; 2014 Feb; 7():15. PubMed ID: 24565018
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.